Kling Bio has announced a collaboration and license option agreement with Sanofi to accelerate the discovery of antibodies and epitopes using its B cell immortalisation and screening platform, Kling-Select.

The platform uses patient-derived B cells to identify rare antibodies and conserved viral epitopes, which can inform the design of vaccines and therapeutics. It has previously been applied to the discovery of antibody candidates against RSV, COVID-19 and influenza.

The new partnership will focus on identifying monoclonal antibodies with strong neutralising activity against a clinically relevant human viral pathogen. The findings could support the development of new antiviral treatments and vaccines.

Michael Koslowski, chief executive officer at Kling Bio, said: “This collaboration with Sanofi highlights the broad potential of our Kling-Select platform to address global health challenges. It provides a powerful window into the human immune response and accelerates the identification of functional antibodies and novel epitopes. We are excited to combine our expertise with Sanofi’s leadership in vaccine development to advance next-generation therapeutics and vaccines.”